In a report released on April 22, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 15 unusual trades. Delving into the details, we found 46% of ...

Blue Prince is a game full of things to discover. That said, when you first start Blue Prince, you're given two main objectives: Reach the Antechamber and Find Room 46. You'll need to complete ...

Danish pharma major Novo Nordisk (NOV: N) has announced an investment of $1.1 billion to expand its production facility in Brazil’s Montes Claros, northern Minas Gerais, with the aim of increasing ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024, the share price was over DKK 1,000 per share. Now it is approaching DKK 400.The latest dip comes on Wednesday morning ...